With the recent approval of tolterodine and oxybutynin XL, we believe that the list of agents previously considered first- and second-line medications for the overactive bladder needs to be revised.
An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...
The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.
Drugs to treat overactive bladder don't work very well, according to a recent CR Best Buy Drugs analysis. Studies have found that only a small proportion of people get full relief of their ...
Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...
Understanding available treatment options ... often improves nighttime bladder control. Some individuals find complementary therapies helpful in managing bladder control issues. Acupuncture shows ...
This is called an Overactive Bladder ( OAB ... assess both the storage and voiding phases of the urinary bladder. What are the treatment options available ? The conservative strategies to ...
HealthDay on MSN6d
FDA Approves Gemtesa for Overactive Bladder in Men With BPHGemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback